



Market Announcement

23 March 2020

MGC Pharmaceuticals Limited (ASX: MXC) – Suspension from Official Quotation

Description

The securities of MGC Pharmaceuticals Limited ('MXC') will be suspended from quotation immediately under Listing Rule 17.2, at the request of MXC, pending the release of an announcement regarding a strategic joint venture with a Swiss company.

Issued by

Daniel Nicholson

Adviser, Listings Compliance (Perth)

23 March 2020

Australian Securities Exchange
Level 40, Central Park
152-158 St Georges Tce
Perth WA 6000

Via email: tradinghaltspert@asx.com.au

Dear Sir/Madam

MGC Pharmaceuticals Ltd – Voluntary Suspension Request

Pursuant to ASX Listing Rule 17.2, MGC Pharmaceuticals Ltd (ASX: MXC) (the “Company”) requests a voluntary suspension over the Company’s securities from the commencement of trade on Monday 23 March 2020.

In accordance with ASX Listing Rule 17.2 the Company provides the following information regarding the request:

1. The voluntary suspension request by the Company is to allow finalisation of an announcement on a material agreement regarding a strategic joint venture with a Swiss company in relation to COVID-19.
2. The Company expects the voluntary suspension to end no later than the commencement of trade on Tuesday 24 March 2020, when it anticipates it will be in a position to make a detailed announcement to the market in respect of the abovementioned transaction.
3. The Company is not aware of any reason why the voluntary suspension should not be granted, nor of any other information necessary to inform the market about the voluntary suspension.

On behalf of the Board

[signed electronically without signature]

Brett Mitchell
Executive Chairman
MGC Pharmaceuticals Ltd